The Oncology Institute Inc Down 15.76% To $1.55 After Earnings Miss

The Oncology Institute Inc (TOI) said after close Wednesday that it lost $0.21 per share in quarter four 2023.

On the revenue line, the company reported $85.8 million, beating estimates by $3.7 million.

In the same quarter a year ago, the company lost $0.15 per share on revenue of $71.4 million.

The stock is down 15.76% to $1.55 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

The Oncology Institute Inc has performed a little below average during the past few months. Before the report, The Oncology Institute Inc received a Long-Term Technical Rank by InvestorsObserver of 29, putting it in the bottom half of stocks. The firm set a 52-week high on November 13, 2023 at $2.66 and set a 52-week low on June 5, 2023 at $0.33.

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financia, counseling, clinical trials, comprehensive lab testing, and end-of-life counseling.The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.